Source:http://linkedlifedata.com/resource/pubmed/id/16315020
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2006-3-9
|
pubmed:abstractText |
Alpha-methylacyl-CoA racemase (AMACR/P504S) is a useful biomarker of prostate cancer. We evaluated the expression of AMACR in upper urinary tract urothelial carcinomas with respect to associations with tumour stage, grade and metastasis-free survival. A total of 268 tumours were investigated immunohistochemically using a tissue microarray technique. AMACR expression was noted in 127 of 261 (48.7%) evaluated tumours and was associated with high tumour stage [58 of 139 (41.7%) pTa/pT1 vs. 69 of 122 (56.6%) pT2-pT4, P=0.019] and high tumour grade [44 of 137 (32.1%) low vs. 83 of 124 (66.9%) high grade, P<0.001]. In addition, AMACR expression was associated with the presence of tumour necrosis (P<0.001) and marked stromal desmoplasia (P=0.0026). This correlation indicates that increased AMACR expression might be related to hypoxia-induced changes in cancer cell metabolism, such as increased dependence on fatty acid oxidation for energy generation. Progressive disease was observed in 73 of 183 (39.9%) patients with solitary invasive carcinomas and was associated with AMACR expression (P=0.017). Multivariate analysis, however, proved only pT-stage >1 (P<0.001) and high tumour grade (P<0.001) to be independent predictors of patient outcome. In conclusion, AMACR expression correlated with advanced tumour stage and grade and may serve as an additional prognostic indicator in upper urinary tract urothelial cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0945-6317
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
448
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
325-30
|
pubmed:meshHeading |
pubmed-meshheading:16315020-Adult,
pubmed-meshheading:16315020-Aged,
pubmed-meshheading:16315020-Aged, 80 and over,
pubmed-meshheading:16315020-Carcinoma, Transitional Cell,
pubmed-meshheading:16315020-Disease-Free Survival,
pubmed-meshheading:16315020-Female,
pubmed-meshheading:16315020-Humans,
pubmed-meshheading:16315020-Kidney Neoplasms,
pubmed-meshheading:16315020-Male,
pubmed-meshheading:16315020-Middle Aged,
pubmed-meshheading:16315020-Proportional Hazards Models,
pubmed-meshheading:16315020-Racemases and Epimerases,
pubmed-meshheading:16315020-Survival Rate,
pubmed-meshheading:16315020-Tumor Markers, Biological,
pubmed-meshheading:16315020-Ureteral Neoplasms
|
pubmed:year |
2006
|
pubmed:articleTitle |
Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.
|
pubmed:affiliation |
Institute of Pathology, Medical University Graz, Auenbruggerplatz 25, Graz, Austria. cord.langner@meduni-graz.at
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|